Effect of amphotericin B associated with a lipid emulsion on the oxidative burst of human polymorphonuclear leukocytes |
| |
| Affiliation: | 1. Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences, Dr. H. S. Gour Central University, Sagar, India;2. Pharmaceutical Nanotechnology Research Laboratory, ISF College of Pharmacy, Moga, India;3. Pharmaceutics Division, CSIR–Central Drug Research Institute, Sector 10, Jankipuram Extension, Lucknow, India;1. Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, School of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain;2. Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Granada, Granada, Spain;3. Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Barcelona, Spain;4. Department of Biology, Healthcare and the Environment, School of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain;1. TOBB University of Economics and Technology, Department of Mechanical Engineering, Ankara 06560, Turkey;2. TUBITAK Defense Industries Research and Development Institute, P.K. 16 06261 Mamak, Ankara, Turkey |
| |
| Abstract: | ![]()
- 1.1. Despite its toxicity, amphotericin B (AB) continues to be the drug of choice for the treatment of systemic fungal infection. The drug acts on several cell types, including polymorphonuclear leukocytes (PMN), where it inhibits the oxidative burst of cells submitted to several stimuli.
- 2.2. It was previously shown that the association of AB with a triglyceride-rich emulsion that physiologically mimics chylomicrons reduces toxicity.
- 3.3. We found that the association of AB with a triglyceride-rich emulsion reduces the loss of PMN viability produced by the drug.
- 4.4. The inhibition of the PMN oxidative burst triggered by phorbol 12-myristate 13-acetate (PMA) and opsonized zymosan (OZ) also was decreased by the association of the drug with this lipid emulsion.
- 5.5. Delivery of AB in a lipid emulsion may be of advantage in the treatment of immunosuppressed patients.
|
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
